1. Medicine

Category Archives: Medicine

Sports Medicine Pioneer Frank Jobe Dies At 88

Posted on by

LOS ANGELES (AP) Dr. Frank Jobe, a pioneering orthopedic surgeon who was the first to perform an elbow procedure that became known as Tommy John surgery and saved the careers of countless major league pitchers, died Thursday. He was 88.

Jobe died in Santa Monica after being hospitalized recently with an undisclosed illness, according to a spokesman for the Los Angeles Dodgers.

Jobe performed groundbreaking elbow surgery on John, a Dodgers pitcher who had a ruptured medial collateral ligament in his left elbow. The injury previously had no solution until Jobe removed a tendon from John's forearm and repaired his elbow. John went on to pitch 14 years after the operation on Sept. 25, 1974, compiling 164 more victories without ever missing a start because of an elbow problem.

"Today I lost a GREAT friend," John tweeted.

Last year, the initial surgery and the relationship between John and Jobe was the subject of an ESPN documentary.

"When he did come back, I thought maybe we could do it on somebody else," Jobe told The Associated Press in 2010. "I waited two years to try it on somebody else, but we had no idea we could do it again."

Jobe initially estimated John's chances of returning to the majors at less than 5 percent. He later said 92 to 95 percent of patients return as good, if not better, than before the surgery.

The surgery has since become common practice for pitchers and players at every level of baseball, including New York Mets pitcher Matt Harvey, Washington star Stephen Strasburg, San Francisco's Tim Hudson and Minnesota's Francisco Liriano.

Some pitchers have signed multiyear contracts just months after they have the surgery in expectation of a high-level return.

Typically, full rehabilitation takes about a year for pitchers and about six months for position players. The procedure initially required four hours; now it takes about an hour.

Read the rest here:

Sports Medicine Pioneer Frank Jobe Dies At 88

Animal Science/Pre-veterinary Medicine Accepted Students Live Chat – Video

Posted on by


Animal Science/Pre-veterinary Medicine Accepted Students Live Chat
Animal Science/Pre-veterinary Medicine Accepted Students Live Chat We #39;ll discuss your next steps in the admission process as an accepted student and answer ...

By: Admissions - The University of Findlay

Go here to see the original:

Animal Science/Pre-veterinary Medicine Accepted Students Live Chat - Video

Synbiotic May Help Treat Non Alcoholic Fatty Liver Disease a New Study Finds – Video

Posted on by


Synbiotic May Help Treat Non Alcoholic Fatty Liver Disease a New Study Finds
Please like, subscribe, comment and share! ARTICLE http://ajcn.nutrition.org/content/early/2014/01/08/ajcn.113.068890.short?rss=1 Per the authors, "The objec...

By: Lifestyle Medicine

See the original post here:

Synbiotic May Help Treat Non Alcoholic Fatty Liver Disease a New Study Finds - Video

$3.25 Million Gift Creates Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Posted on by

Contact Information

Available for logged-in reporters only

Newswise PHILADELPHIA Three longtime allies have joined forces to create the new Penn Medicine/CHOP Friedreichs Ataxia Center of Excellence. The establishment of the center was catalyzed by a $3.25 million gift from the Friedreichs Ataxia Research Alliance (FARA), in partnership with the Hamilton and Finneran families.

For the past 16 years Penn Medicine, The Childrens Hospital of Philadelphia (CHOP), and FARA, a nonprofit organization dedicated to curing FA, have collaborated to provide and push forward the care needed by FA patients.

Friedreichs ataxia (FA) is a rare, progressive neurogenetic condition found in approximately 1 in 50,000 people worldwide. While it is relatively rare, it is the most common form of inherited ataxia, a condition characterized by progressive lack of coordinated movement and loss of balance. FA also involves degeneration of heart muscle and nerve cells. Onset of symptoms usually occurs in childhood, and most patients are confined to a wheelchair by their mid-to-late twenties. Myocardial failure and/or arrhythmias are the most common cause of premature death. Currently there are no approved drugs to treat FA.

FARA, CHOP, and Penn Medicine have also shared in research and clinical trials that have elucidated the metabolic dysfunction underlying FA. Their work has created a database of well-documented patients and a pipeline of more than 20 drug candidates ready to be mined for new therapies. Today the FA clinical program at CHOP is the largest in the world.

Nothing is more rewarding than seeing science at work in the service of the patients and families who suffer from rare diseases such as Friedreichs ataxia, says Glen N. Gaulton, PhD, executive vice dean and chief scientific officer at the Perelman School of Medicine at the University of Pennsylvania. Penn and CHOP are fortunate to support many faculty who dedicate their careers to the care of patients with and research on such rare diseases as FA. Funding for rare disease research is a constant challenge. We are thankful to the donors for this generous gift that significantly enhances our ability to make progress toward new biomarkers, drugs and hopefully, in time, therapies for FA.

The new Centers team is working with pharmaceutical industry partners to develop drug candidates as well as biomarkers for FA, and this effort fits alongside a broader initiative at Penn Medicine: a gift from an anonymous donor recently founded the Center for Orphan Disease Research and Therapy to support the pursuit of novel therapies for rare diseases of all kinds.

Integrating cardiac expertise into the care of patients is one major step forward this gift allows us to pursue, says Philip R. Johnson, MD, executive vice president and chief scientific officer at CHOP. Rare diseases are often an area where philanthropy can make a difference, and the generosity of these donors will make a significant impact.

The Friedreichs Ataxia Center of Excellence is co-directed by David Lynch, MD, PhD, FA program director at CHOP, and Robert B. Wilson, MD, PhD, professor of Pathology and Laboratory Medicine at the Perelman School of Medicine. Lynch and Wilson both serve on FARAs Scientific Advisory Board, and Wilson was a founding member of FARAs board of directors and first chairman of its Scientific Review Committee. Wilson has completed a high-throughput drug screen of more than 340,000 compounds for FA drug discovery and is now working with medicinal chemists to narrow in on candidates for clinical trials.

Read more from the original source:

$3.25 Million Gift Creates Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence


  1. Medicine